Target Information
| Target General Information | Top | |||||
|---|---|---|---|---|---|---|
| Target ID |
T87742
(Former ID: TTDI01602)
|
|||||
| Target Name |
Gap junction protein (GJP)
|
|||||
| Gene Name |
NO-GeName
|
|||||
| Target Type |
Clinical trial target
|
[1] | ||||
| Disease | [+] 2 Target-related Diseases | + | ||||
| 1 | Cardiac arrhythmia [ICD-11: BC9Z] | |||||
| 2 | Supraventricular tachyarrhythmia [ICD-11: BC81] | |||||
| UniProt ID | ||||||
| Drugs and Modes of Action | Top | |||||
|---|---|---|---|---|---|---|
| Clinical Trial Drug(s) | [+] 2 Clinical Trial Drugs | + | ||||
| 1 | Danegaptide | Drug Info | Phase 2 | Atrial fibrillation | [2] | |
| 2 | ROTIGAPTIDE | Drug Info | Phase 2 | Cardiac arrhythmias | [3] | |
| Mode of Action | [+] 1 Modes of Action | + | ||||
| Modulator | [+] 2 Modulator drugs | + | ||||
| 1 | Danegaptide | Drug Info | [4] | |||
| 2 | ROTIGAPTIDE | Drug Info | [1] | |||
| References | Top | |||||
|---|---|---|---|---|---|---|
| REF 1 | The antiarrhythmic peptide rotigaptide (ZP123) increases gap junction intercellular communication in cardiac myocytes and HeLa cells expressing connexin 43. Br J Pharmacol. 2006 Mar;147(5):486-95. | |||||
| REF 2 | ClinicalTrials.gov (NCT01977755) Phase 2 Clinical Proof-of-Concept Study of the Cardioprotective Properties of Danegaptide in ST Segment Elevation Myocardial Infarction. U.S. National Institutes of Health. | |||||
| REF 3 | ClinicalTrials.gov (NCT00137332) Study Evaluating GAP-486 on Heart Rhythm in Patients With Coronary Artery Disease. U.S. National Institutes of Health. | |||||
| REF 4 | The gap junction modifier, GAP-134 [(2S,4R)-1-(2-aminoacetyl)-4-benzamido-pyrrolidine-2-carboxylic acid], improves conduction and reduces atrial fibrillation/flutter in the canine sterile pericarditis model. J Pharmacol Exp Ther. 2009 Jun;329(3):1127-33. | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.